Compare · DFTX vs PXMD
DFTX vs PXMD
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $4.56B.
- DFTX has hit the wire 8 times in the past 4 weeks while PXMD has been quiet.
- DFTX has more recent analyst coverage (6 ratings vs 0 for PXMD).
- Company
- Definium Therapeutics Inc.
- PaxMedica Inc.
- Price
- $41.77-3.99%
- $0.72-3.73%
- Market cap
- $4.56B
- -
- 1M return
- -5.55%
- -
- 1Y return
- +345.97%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 8
- 0
- Recent ratings
- 6
- 0
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Wells Fargo initiated coverage on Definium Therapeutics with a new price target
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection